As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...

A group of more than a dozen investors have together purchased a majority stake in HistoSonics, following reports earlier ...

When Tiba Biotech was included in the cancelation of $500 million worth grants funding mRNA vaccine development, the company ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

In its own statement, Edwards said it disagrees with the FTC’s belief that the acquisition will limit access to a new therapy ...

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic.  | Alltrna, the preclinical Flagship ...